tbuckley/cabot-search huggingface dataset:
Management of Chronic Obstructive Pulmonary Disease
Authors: J F Donohue
Journal: JAMA (2004)

Chronic obstructive lung disease affects over 15 million people in the United States. The management of this disease in patients is complex, involving antibiotics, mucolytics, bronchodilators, corticosteroids, and rehabilitation. Several studies investigating controversial areas of management were published in 1993 and 1994. New developments in pulmonary rehabilitation, oxygen therapy, noninvasive ventilation, corticosteroids, bronchodilators, vasodilators for pulmonary hypertension, lung transplantation, lung surgery for bullae, and alpha-1-antitrypsin replacement therapy provide physicians with exciting new opportunities for managing chronic obstructive pulmonary disease.
Transplanted CD34+ Cells Stimulated with Flt3 Ligand and Granulocyte-Colony Stimulating Factor Display An Impaired Early Reconstitution Capacity
Authors: Fati ma SF Aerts Kaya, Simone CC Hartong, Trudi P Visser, Monique MA Verstegen, Albertus W. Wognum, Gerard Wagemaker
Journal: Blood (2008)
Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.
Authors: Tetsuya Nishida, Ana Kostic, David G. Maloney, Rainer F. Storb, Stanley R. Riddell
Journal: Blood (2006)
A Randomized Trial of High-Dose (HD) Imatinib Mesylate (IM) with or without Peg-Interferon (PEG-IFN) and GM-CSF as Frontline Therapy for Patients with Chronic Myeloid Leukemia (CML) in Early Chronic Phase (CP).
Authors: Jorge Cortes, Moshe Talpaz, Susan O’Brien, Farhad Ravandi, Srdan Verstovsek, Guillermo Garcia-Manero, Charles Koller, Michael Andreeff, Zeev Estrov, Hagop Kantarjian
Journal: Blood (2005)
Compartment-Specific Bioluminescence Imaging (CS-BLI) High- Throughput Assays Provide Comparative Insights into the Impact of Osteoclasts Vs. Stromal Cells on Activity of Anti-Myeloma Therapeutics
Authors: Melissa G. Ooi, Douglas W. McMillin, Joseph M. Negri, Jake Delmore, Steffen Klippel, Nicholas Mitsiades, Paul G. Richardson, Kenneth C. Anderson, Constantine S. Mitsiades
Journal: Blood (2008)
Development of a Myeloproliferative Disease or a T Cell Lymphoblastic Leukemia in a Murine Bone Marrow Transplant Model of NUP214-ABL1.
Authors: Jennifer L. Rocnik, Melanie Cornejo, Benjamin H. Lee, Rachel Okabe, Elizabeth McDowell, Maricel Gozo, Kim De Keersmaecker, Jan Cools, D. Gary Gilliland
Journal: Blood (2006)
Safety and Effectiveness of Apixaban, LMWH and Warfarin Among Venous Thromboembolism (VTE) Patients with Active Cancer: A Subgroup Analysis of VTE Risk Scale
Authors: Alexander T Cohen, Allison Keshishian, Theodore Lee, Gail Wygant, Lisa Rosenblatt, Patrick Hlavacek, Jack Mardekian, Daniel Wiederkehr, Janvi Sah, Xuemei Luo
Journal: Blood (2019)
Myopericarditis associated with Echo virus type 3 infection. A case report.
Authors: Takehisa Fukuhara, Masahiko Kinoshita, Keizo Bito, Matsuhiko Sawamura, Masakazu Motomura, Seiichi Kawakita, Katsuyuki Kawanishi
Journal: Circulation (1983)

A case with myopericarditis caused by type 3 ECHO virus was reported. The diagnosis was based on a significantly increased hemagglutination-inhibiting antibody titer (from 4 :6 to 4: 516) against type 3 ECHO virus in the acute and the convalescent phase. A 29-year-old male was hospitalized for chest pain and fever. The patient had congestive heart failure, pericardial effusion and temporarily appearing abnormal Q waves on his electrocardiogram in the acute phase all of which gradually improved within about 3 weeks. Cardiac catheterization performed on the 21 st day of hospitalization disclosed normal coronary arteries, but a partially hypokinetic region was found in the left ventricular free wall. A right ventricular endomyocardial biopsy study revealed histological features of a small number of mononuclear cell infiltrations, myocardial cell necrosis and early fibrosis associated with an increased number of fibroblasts and ultrastructural changes including myocytolysis, vacuolation in sarcoplasm and dissociation of some intercalated discs. The endomyocardial biopsy study, and the electrocardiographic and cineangiographic findings in this case suggest that viral infection may induce clinical signs of myocardial infarction in the heart with normal coronary arteries.
Idiopathic pneumopericardium induced by forced coughing during coronary arteriography.
Authors: Kiyoshi Ishii, Yasunori Koga, Kenji Araki
Journal: Circulation (1987)

We report the induction of pneumopericardium by forced coughing during coronary arteriography in a 31-year-old male with anterior chest pain. The patient had no underlying disease and pneumopericardium could be reproduced by forced coughing. To our knowledge, there has been no report in the literature of pneumopericardium induced during coronary arteriography.
Evaluation of the management of pretreatment HIV drug resistance by oligonucleotide ligation assay: a randomised controlled trial
Authors: Michael H Chung, Christine J McGrath, Ingrid A Beck, Molly Levine, Ross S Milne, Isaac So, Nina Andersen, Sandra Dross, Robert W Coombs, Bhavna Chohan, Nelly Yatich, Catherine Kiptinness, Samah R Sakr, James N Kiarie, Lisa M Frenkel
Journal: The Lancet HIV (2019)
Gene-Gene Interactions and the Pathophysiology of Sickle Cell Disease: Modeling the Effects of SNPs on Sickle Cell-Associated Vasoocclusive Events Using Classification and Regression Trees and Stochastic Gradient Boosting.
Authors: Vikki G. Nolan, Marsha A. Wilcox, Paola Sebastiani, Clinton T. Baldwin, Diego F. Wyszynski, Qianli Ma, Alice Bisbee, John J. Farrell, Lindsay A. Farrer, Martin H. Steinberg
Journal: Blood (2005)
Myeloid-Lineage Enhancers Drive Oncogene Synergy and Represent a Novel Therapeutic Target in CSF3R-CEBPA Mutant AML
Authors: Theodore Braun, Cody Coblentz, Sarah A Carratt, Mariam Okhovat, Amy Foley, Zachary Schonrock, Kimberly Nevonen, Rhonda E. Ries, Shannon K. McWeeney, Claus Nerlov, Soheil Meshinchi, Lucia Carbone, Brian J. Druker, Julia E. Maxson
Journal: Blood (2019)
BEACOPP Chemotherapy Is Able to Induce Durable Complete Remission in Poor-Prognosis Hodgkin’s Lymphoma Patients with a Positive Interim PET after 2 ABVD Cycles
Authors: Andrea Gallamini, Alessandro Rambaldi, Alberto Biggi, Silvia Tavera, Caterina Patti, Caterina Stelitano, Alessandro M. Gianni, Francesco Di Raimondo, PierFederico Torchio, Andrea Rossi, Alessandro Mistretta, Simonetta Viviani, Alessandra Chiarenza, Paolo Gavarotti, Corrado Tarella
Journal: Blood (2008)
Assessment of Longer-Term Efficacy and Safety in the Phase 3, Randomized, Double-Blind, Placebo-Controlled MEDALIST Trial of Luspatercept to Treat Anemia in Patients (Pts) with Revised International Prognostic Scoring System (IPSS-R) Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions
Authors: Pierre Fenaux, Ghulam J. Mufti, Rena Buckstein, Valeria Santini, María Díez-Campelo, Carlo Finelli, Mario Cazzola, Osman Ilhan, Mikkael A. Sekeres, Rami S. Komrokji, Alan F. List, Amer M. Zeidan, Amit Verma, Abderrahmane Laadem, Rodrigo Ito, Jennie Zhang, Anita Rampersad, Daniel Sinsimer, Peter G. Linde, Guillermo Garcia-Manero, Uwe Platzbecker
Journal: Blood (2019)
Feasability of High Dose Melphalan and Peripheral Blood Stem Cell Support(IPC-LAM 2000) for Patients over 60 Years with Acute Myeloid Leukemia(AML) in First Remission(CR1):Final Analysis.
Authors: Anne-Marie Stoppa, Norbert Vey, Reda Bouabdallah, Catherine Faucher, Diane Coso, Aude Charbonnier, Jean Marc Schianno, Therese Aurran, Christian Chabannon, Danielle Sainty, Marina Lafage, Didier Blaise, Jean Albert Gastaud, Dominique Maraninchi
Journal: Blood (2005)
Outcomes of Women Compared With Men After Non–ST-Segment Elevation Acute Coronary Syndromes
Authors: Amy A Sarma, Eugene Braunwald, Christopher P Cannon, Jianping Guo, KyungAh Im, Elliott M Antman, C Michael Gibson, L Kristin Newby, Robert P Giugliano, David A Morrow, Stephen D Wiviott, Marc S Sabatine, Michelle L O'Donoghue
Journal: Journal of the American College of Cardiology (2019)
发展中国家的癫痫治疗——药物便宜而有效，但大部分患者未接受治疗
Authors: 张华（译）
Journal: BMJ (2007)

生活在发展中国家的3500万癫痫患者中，大约85％根本未接受过任何治疗。其结果是，这些患者不仅会发生癫痫发作，而且还会产生自卑心理，忍受社会歧视。遗憾的是，绝大多数患者，其中大部分是儿童，可以通过每天口服1次价值低于3美元（合1．50英镑；2．20欧元）的药物而完全得到控制并能够恢复正常生活。在本期BMJ中（见第272页），来自孟加拉国的Banu及其同事对卡马西平和苯巴比妥在108名儿童癫痫患者治疗中的疗效和行为学副作用进行了随机对照研究。
Combined effects of rapamycin and bicalutamide in androgen-dependent and -independent prostate cancer cells
Authors: Yu Wang, Margarita Mikhailova, Ralph devere White, Paramita Ghosh
Journal: Cancer Research (2008)

2760  In the initial stages, prostate tumors are dependent on androgens for growth, and hence, recurrent prostate cancer is primarily treated by androgen deprivation therapy. Patients respond initially to such treatment but ultimately relapse indicative of the development of androgen-independent prostate cancer (AIPC). The mTOR inhibitor rapamycin prevented the growth of both androgen-dependent and androgen-independent cell lines in short-term studies, and hence was promising as treatment for prostate cancer. However, long-term treatment with rapamycin induced resistance to this drug. Here we show that mTOR forms two complexes mTORC1 (mTOR/raptor/GβL) and mTORC2 (mTOR/rictor/sin1/GβL), both of which are inhibited by rapamycin. However, over time, rapamycin depleted rictor levels, thereby decreasing mTORC2 and forcing the drug to act through mTORC1 alone. Inhibition of mTORC1 by rapamycin inhibited cell growth but also stimulated Akt phosphorylation and AR transcriptional activity. Stimulation of AR transcriptional activity promoted cell growth and diminished the growth-inhibitory effects of rapamycin. On the other hand, rapamycin inhibition of mTORC2 inhibited cell growth as well as AR transcriptional activity. Therefore, depletion of rictor and rapamycin inhibition of mTORC1 alone caused the delayed resistance to rapamycin. To overcome rapamycin-resistance caused by AR transcriptional activity stimulated by the inhibition of mTORC1, we used the AR antagonist bicalutamide. Simultaneous treatment with bicalutamide inhibited AR transcriptional activity, thereby sensitizing the cells to the growth inhibitory effects of rapamycin. Our data shows that a combination of rapamycin and bicalutamide would be effective therapy for the treatment of prostate cancer.
Activation of JNK and p38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression
Authors: Xueran Chen, Aijun Hao, Xian Li, Kaiqin Ye, Chenggang Zhao, Haoran Yang, Huihui Ma, Lei Hu, Zhiyang Zhao, Lizhu Hu, Fang Ye, Qiuyan Sun, Huaman Zhang, Hongzhi Wang, Xuebiao Yao, Zhiyou Fang
Journal: Theranostics (2019)

Rationale: Glioblastoma multiforme (GBM) almost invariably gain invasive phenotype with limited therapeutic strategy and ill-defined mechanism. By studying the aberrant expression landscape of gliomas, we find significant up-regulation of p-MAPK level in GBM and a potent independent prognostic marker for overall survival. DHHC family was generally expressed in glioma and closely related to the activation of MAPK signaling pathway, but its role and clinical significance in GBM development and malignant progression are yet to be determined. Method: Bioinformatics analysis, western blotting and immunohistochemistry (IHC) were performed to detect the expression of ZDHHC17 in GBM. The biological function of ZDHHC17 was demonstrated by a series of in vitro and in vivo experiments. Pharmacological treatment, flow cytometry, Transwell migration assay, Co- Immunoprecipitation and GST pulldown were carried out to demonstrate the potential mechanisms of ZDHHC17. Results: ZDHHC17 is up-regulated and coordinated with MAPK activation in GBM. Mechanistically, ZDHHC17 interacts with MAP2K4 and p38/JNK to build a signaling module for MAPK activation and malignant progression. Notably, the ZDHHC17-MAP2K4-JNK/p38 signaling module contributes to GBM development and malignant progression by promoting GBM cell tumorigenicity and glioma stem cell (GSC) self-renewal. Moreover, we identify a small molecule, genistein, as a specific inhibitor to disrupt ZDHHC17-MAP2K4 complex formation for GBM cell proliferation and GSC self-renewal. Moreover, genistein, identified herein as a lead candidate for ZDHHC17-MAP2K4 inhibition, demonstrated potential therapeutic effect in patients with ZDHHC17-expressing GBM. Conclusions: Our study identified disruption of a previously unrecognized signaling module as a target strategy for GBM treatment, and provided direct evidence of the efficacy of its inhibition in glioma using a specific inhibitor.
Norepinephrine metabolite DOPEGAL activates AEP and pathological Tau aggregation in locus coeruleus
Authors: Seong Su Kang, Xia Liu, Eun Hee Ahn, Jie Xiang, Fredric P. Manfredsson, Xifei Yang, Hongbo R. Luo, L. Cameron Liles, David Weinshenker, Keqiang Ye
Journal: Journal of Clinical Investigation (2019)

Aberrant Tau inclusions in the locus coeruleus (LC) are the earliest detectable Alzheimer's disease-like (AD-like) neuropathology in the human brain. However, why LC neurons are selectively vulnerable to developing early Tau pathology and degenerating later in disease and whether the LC might seed the stereotypical spread of Tau pathology to the rest of the brain remain unclear. Here, we show that 3,4-dihydroxyphenylglycolaldehyde, which is produced exclusively in noradrenergic neurons by monoamine oxidase A metabolism of norepinephrine, activated asparagine endopeptidase that cleaved Tau at residue N368 into aggregation- and propagation-prone forms, thus leading to LC degeneration and the spread of Tau pathology. Activation of asparagine endopeptidase-cleaved Tau aggregation in vitro and in intact cells was triggered by 3,4-dihydroxyphenylglycolaldehyde, resulting in LC neurotoxicity and propagation of pathology to the forebrain. Thus, our findings reveal that norepinephrine metabolism and Tau cleavage represent the specific molecular mechanism underlying the selective vulnerability of LC neurons in AD.
Vital Signs: Current Cigarette Smoking Among Adults Aged ≥18 Years with Mental Illness — United States, 2009–2011
Authors: Joe Gfroerer, Shanta R. Dube, Brian A. King, Bridgette E. Garrett, Stephen Babb, Timothy McAfee
Journal: MMWR Morbidity and Mortality Weekly Report (2013)

Background
Cigarette smoking remains the leading cause of preventable morbidity and mortality in the United States. Despite overall declines in cigarette smoking, a high prevalence of smoking persists among certain subpopulations, including persons with mental illness.
Tymic Output after Autologous Bone Marrow Transplantation (ASCT) HIV-Related Lymphoma.
Authors: Cecilia Simonelli, Michele Spina, Chiara Pratesi, Rosamaria Tedeschi, Maurizio Rupolo, Maria Teresa Bortolin, Stefania Zanussi, Mariagrazia Michieli, Paolo De Paoli, Umberto Tirelli
Journal: Blood (2005)
Abstract 10066: Cholesterol Efflux Capacity & Collateral Circulation in Patients With Chronic Total Coronary Occlusion
Authors: Seonhwa Lee, Eun Jeong Cheon, Chan Joo Lee, Jaewon Oh, Sungha Park, SeokMin kang, Sang-Hak Lee
Journal: Circulation (2019)

Introduction: Although a recent study suggested high-density lipoprotein (HDL)-mediated cholesterol efflux can modulate angiogenesis in animal model, its role in human vascular disease has not been...
Abstract 15572: A Pragmatic Approach to Risk Assessment in Pulmonary Arterial Hypertension Using the ESC/ERS Guidelines
Authors: Fabio Dardi, Alessandra Manes, Gerardo Vito Lo Russo, Andrea Rinaldi, Enrico Gotti, Elisa Zuffa, Alessandro De Lorenzis, Filippo Pasca, Andrea Cassani, Daniele Guarino, Massimiliano Palazzini, Nazzareno Galiè
Journal: Circulation (2018)

Introduction: The 2015 ESC/ERS pulmonary hypertension (PH) guidelines propose a risk stratification strategy for patients with pulmonary arterial hypertension (PAH) based on a multiparametric appro...
2-Chlorodeoxyadenosine in refractory non-Hodgkin's lymphoma: A phase II study on 50 patients.
Authors: André Bosly, Augustin Ferrant, Anne Sonet, André Delannoy, Guy Cornu, Jl. Canon, P. Martiat, Nicole Straetmans, C Ravoet, P. Mineur, C Laszlo, Jacques Jamart, Chantal Doyen, Jl. Michaux
Journal: Blood (1995)
Clinical Pig Kidney Xenotransplantation: How Close Are We?
Authors: David K. C. Cooper, Hidetaka Hara, Hayato Iwase, Takayuki Yamamoto, Abhijit Jagdale, Vineeta Kumar, Roslyn Bernstein Mannon, Michael J. Hanaway, Douglas J. Anderson, Devin E. Eckhoff
Journal: Journal of the American Society of Nephrology (2019)

Patients with ESKD who would benefit from a kidney transplant face a critical and continuing shortage of kidneys from deceased human donors. As a result, such patients wait a median of 3.9 years to receive a donor kidney, by which time approximately 35% of transplant candidates have died while waiting or have been removed from the waiting list. Those of blood group B or O may experience a significantly longer waiting period. This problem could be resolved if kidneys from genetically engineered pigs offered an alternative with an acceptable clinical outcome. Attempts to accomplish this have followed two major paths: deletion of pig xenoantigens, as well as insertion of “protective” human transgenes to counter the human immune response. Pigs with up to nine genetic manipulations are now available. In nonhuman primates, administering novel agents that block the CD40/CD154 costimulation pathway, such as an anti-CD40 mAb, suppresses the adaptive immune response, leading to pig kidney graft survival of many months without features of rejection (experiments were terminated for infectious complications). In the absence of innate and adaptive immune responses, the transplanted pig kidneys have generally displayed excellent function. A clinical trial is anticipated within 2 years. We suggest that it would be ethical to offer a pig kidney transplant to selected patients who have a life expectancy shorter than the time it would take for them to obtain a kidney from a deceased human donor. In the future, the pigs will also be genetically engineered to control the adaptive immune response, thus enabling exogenous immunosuppressive therapy to be significantly reduced or eliminated.
The role of cathepsin D in the pathophysiology of heart failure and its potentially beneficial properties: a translational approach
Authors: Martijn F. Hoes, Jasper Tromp, Wouter Ouwerkerk, Nils Bomer, Silke U. Oberdorf‐Maass, Nilesh J. Samani, Leong L. Ng, Chim C. Lang, Pim van der Harst, Hans Hillege, Stefan D. Anker, Marco Metra, Dirk J. van Veldhuisen, Adriaan A. Voors, Peter van der Meer
Journal: European Journal of Heart Failure (2019)
Ph-Abnormal Clones Emerged during Imatinib Therapy: Clinical Report and Clonal Analyses on 23 Patients from GIMEMA Working Party (GWP) in CML Registry.
Authors: Elisabetta Abruzzese, Alessandro Gozzetti, Alfonso Zaccaria, Nicoletta Testoni, Sara Galimberti, Malgorzata M. Trawinska, Tommaso Caravita, Paola Panetta, Marco Mancini, Dario Ferrero, Michela Salvio, Franca Radaelli, Federica Sora’, Gianantonio Rosti, Sergio Amadori, Michele Baccarani
Journal: Blood (2004)
Managing health care in a universal bed model system to improve patient outcomes and cost savings after lobectomy procedures.
Authors: V L Sales, Brian T. Nam, Wassim Abi Jaoude, Jamie M Key, Wendy M Horton, Tracey L. Weigel
Journal: Journal of Clinical Oncology (2013)

e17595 Background: We measured our outcomes before and after thoracic universal bed (UB) model implementation for patients undergoing lobectomy for primary lung cancer. Methods: 630 patients with primary lung cancer underwent lobectomy: 198 open thoracotomy (OL) patients before (1/2001-12/2005) and 432 patients (1/2006-12/2011) either via OL (n= 258) or via video-assisted thoracoscopy (VATS) (n=174) after transitioning to the thoracic UB model. Results: Discharge mortality was zero post-UB implementation (vs. 2% pre-UB; p&lt;0.05). 30-day mortality was equivalent (pre-UB 4% vs. UB: OL1%, VATS 0%; p=0.2). Postoperative complications were lower in the UB model (Pre-UB 41% vs. UB: OL 26%, VATS 20%; p &lt;0.001), and similar for OL vs. VATS post-UB (p=0.2). Median length of ICU stay was 0 days (pre-UB IQR 29 vs. UB: OL IQR 14, VATS IQR 3; p &lt;0.001; UB: OL vs. VATS; p=0.2). Median length of stay (LOS) was decreased in the UB model and in VATS post-UB (pre UB 5 days vs. UB: OL 3, VATS 2 days; p &lt; 0.001; UB OL vs. VATS, p &lt; 0.001, respectively) with no difference in readmissions (8% vs. 7%, 8%; p=0.9; UB: OL vs. VATS, p=1.0 respectively). Mean total hospital costs fell 37% from $ 24,423 per patient to $ 15,434 post- UB (p&lt;0.05), and similar for OL vs. VATS in the UB model (OL $ 15, 711 vs. VATS $15,022; p=0.2). Home-discharge was more common in UB patients (pre-UB 91% vs. UB: OL 98%, VATS 94%; p &lt;0.05), and similar for OL vs. VATS post-UB (p=0.1). Postoperative chemotherapy and or radiotherapy treatment were similar (pre-UB 31% vs. UB: OL 37%, VATS 22%; p=0.9). Survival rates were similar at 1, 3, 5 years (pre-UB 89%, 72%, 62% vs. UB: OL 89%,69%, 63%, VATS 92%, 81% and 69%, p=0.6). Complications, LOS and chest tube duration were independent predictors of higher cost in the multivariable analysis in favor of the UB model. Non-home discharge and absence of initial postoperative follow-up within or ≥ 4 months were independent predictors of perioperative mortality and poor survival, respectively, in favor of the UB model. Conclusions: The thoracic UB care model is patient-centered, outcomes-driven, value-based approach focused on safety of patients and efficiency of postoperative care.
In Vivo Purging Followed by AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) in PATIENTS with MULTIPLE MYELOMA (MM): Preliminary RESULTS of a Pilot STUDY
Authors: Imma Attolico, Domenico Vertone, Nunzio Filardi, Michele Pizzuti, Monica Poggiaspalla, Michele Cimminiello, Sabrina Coluzzi, Attilio Olivieri
Journal: Blood (2008)